The Mystery of Mischievous Mucormycosis, Life and Death Dilemma

International Journal of Medical Science

© 2021 by SSRG - IJMS Journal

Volume 8 Issue 1

Year of Publication : 2021

Authors : Raghavendra Rao M.V, Mohammed Khaleel, Srinivasa Rao.D, Adarsh Meher Nisanth, Dilip Mathai, Mohammad Azeeza Siddiqa, G. Suvarna, Jithendra Kumar Naik.S, Ahmad Abdul Khabeer

10.14445/23939117/IJMS-V8I1P101

How to Cite?

Raghavendra Rao M.V, Mohammed Khaleel, Srinivasa Rao.D, Adarsh Meher Nisanth, Dilip Mathai, Mohammad Azeeza Siddiqa, G. Suvarna, Jithendra Kumar Naik.S, Ahmad Abdul Khabeer, "The Mystery of Mischievous Mucormycosis, Life and Death Dilemma," SSRG International Journal of Medical Science, vol. 8,  no. 1, pp. 1-4, 2021. Crossref, https://doi.org/10.14445/23939117/IJMS-V8I1P101

Abstract:

Mucormycosis (also called zygomycosis) is a rare infection caused by organisms that belong to a group of fungi called Mucoromycotina in the order Mucorales. These fungi are typically found in the soil and associated with decaying organic matter, such as leaves, compost piles, or rotten wood. Saprophytic zygomycetes (Eg . Mucor, Rhizopus) are found in tissues of hosts. In persons with diabetes, extensive burns, leukemia, lymphoma, or other chronic illness or immunosuppression. Rhizopus species, Mucor species, and other zygomycetes invade proliferate in the walls of blood vessels, producing thrombosis. Of note, due to its relatively limited activity, itraconazole prophylaxis in immunosuppressed patients may select the fungi in phylum Zygomycota as the cause of infections. Rhino cerebral infections Usually occur during a DKA episode, disrupting host defense mechanisms, thereby permitting Rhizopus oryzae. The correction of acidosis inhibits such growth. The clinical characters are nasal stuffiness, epistaxis, and facial pain. Later, proptosis, chemosis, and ophthalmoplegia. Fever and confusion. Black necrotic eschar on the nasal turbinates or palate.

Keywords:

Mucormycosis, Pulmonary mucormycosis, Leukemia, Neutropenia, Necrotizing Fasciitis.

References:

[1] Hibbett DS, Binder M, Bischoff JF et al., A higher-level phylogenetic classification of the Fungi. Mycol Res., 111(2007), 509–547.
[2] Roden MM, Zaoutis TE, Buchanan WL et al. . Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 41 (2005), 634–653.
[3] Bitar D, Van Cauteren D, Lanternier F et al. Increase incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis., 15(2009),1395–1401.
[4] Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective Antifungal Therapy (PATH) Alliance(®): focus on mucormycosis. Mycoses. 57(2014), 240–246.
[5] Richardson M., Richardson M.D., Warnock D.W. Fourth Edition. Wiley-Blackwell Publishing, Inc.; Chichester, UK. Fungal Infection: Diagnosis and Management, (2012).
[6] Ibrahim Ashraf S., Spellberg Brad, Walsh Thomas J., KontoyiannisDimitrios P. Pathogenesis of mucormycosis. Clin.Infect.Dis., (2012),54 (Suppl._1)): S16–S22.
[7] Chayakulkeeree M, Ghannoum MA, Perfect JR: Zygomycosis: the re-emerging fungal infection. Eur J Microbiol Infect Dis. 25(2006), 215-229.
[8] Ribes, J.A.; Vanover-Sams, C.L.; Baker, D.J. Zygomycetes in Human Disease. Clin. Microbiol. Rev., 13, (2000),236–301.
[9] Richardson, M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin. Microbiol. Infect., 15(2009), 2–9.
[10] Roden, M.M.; Zaoutis, T.E.; Buchanan, W.L.; Knudsen, T.A.; Sarkisova, T.A.; Schaufele, R.L.; Sein, M.; Sein, T.; Chiou, C.C.; Chu, J.H.; et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin. Infect. Dis. 41(2005), 634–653.
[11] Jeong, W.; Keighley, C.; Wolfe, R.; Lee, W.L.; Slavin, M.A.; Kong, D.C.M.; Chen, S.C.A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 25(2019), 26–34
[12] Prakash, H.; Ghosh, A.K.; Rudramurthy, S.M.; Singh, P.; Xess, I.; Savio, J.; Pamidimukkala, U.; Jillwin, J.; Varma, S.; Das, A.; et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med. Mycol., (2018).
[13] Chakrabarti, A.; Das, A.; Mandal, J.; Shivaprakash, M.R.; George, V.K.; Tarai, B.; Rao, P.; Panda, N.; Verma, S.C.; Sakhuja, V. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 44 (2006), 335–342.
[14] Skiada, A.; Pagano, L.; Groll, A.; Zimmerli, S.; Dupont, B.; Lagrou, K.; Bouza, E.; Klimko, N.; Gaustad, P.; Lass-Florl, C.; et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin. Microbiol. Infect., 17(2011), 1859–1867.
[15] Rammaert, B.; Lanternier, F.; Zahar, J.-R.; Dannaoui, E.; Bougnoux, M.-E.; Lecuit, M.; Lortholary, O. Healthcare-associated mucormycosis. Clin. Infect. Dis., (2012), 54 (Suppl. 1), S44–S54.
[16] Jeong W., Keighley C., Wolfe R., Lee W.L., Slavin M.A., Kong D.C.M., Chen S.C.A. The epidemiology and clinical manifestations of mucormycosis: A systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. (2019),25:2634.doi:10.1016/j.cmi.2018.07.011.
[17] Prakash H., Ghosh A.K., Rudramurthy S.M., Singh P., Xess I., Savio J., Pamidimukkala U., Jillwin J., Varma S., Das A., et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med. Mycol., (2018) .doi: 10.1093/mmy/myy060.
[18] Sahota R, Gambhir R, Anand S, Dixit A. Rhino cerebral mucormycosis: Report of a rare case. Ethiop J Health Sci., (2017),27:85–90.
[19] Berdai MA, Labib S, Harandou M. Rhinocerebralmucormycosis complicating ketoacidosis diabetes. Presse Med. (2016),45:145–6.
[20] Dimaka K, Mallis A, Naxakis SS, Marangos M, Papadas TA, Stathas T, et al. Chronic rhino cerebral mucormycosis: A rare case report and review of the literature. Mycoses. (2014),57:699–702.
[21] CK12-Foundation, flexbooks.ck12.org. Retrieved 2020-05-19.
[22] Redecker,D; Kodner, R.; Graham,L.E..Glomalean Fungi from the Ordovician.,Science. 289 (5486),(2000),19201. Bibcode:2000Sci...289.1920R.
[23] Butterfield,N.J..Probable,Proterozoic fungi., Paleobiology. 31 (1), (2005), 165–182.
[24] Wang, D.Y.C.; Kumar, S., Hedges, S.B., Divergence time estimates for the early history of animal phyla and the origin of plants, animals, and fungi., Proceedings of the Royal Society of London B. 266 (1415), (1999),163–171.
[25] Brundrett M.C., Coevolution of roots and mycorrhizas of land plants,. New Phytologist. 154 (2),(2002), 275–304
[26] Yuan X, Xiao S, Taylor TN; Xiao; Taylor. ,Lichen-like symbiosis 600 million years ago,. Science. 308(5724),(2005),1017–20.
[27] Akash Verma, Marcel Wuthrich, George Deepe, and Bruce Klein; Adaptive immunity to
[28] fungi, a subject collection from fungal Human fungal pathogens, Gold spring harbor perspective in medicine, 93.
[29] PoddighiD,MathiasCB,Freyschmidt EJ, Kombi D,et al.2014.Basophils are rapidly mobilized following initial aeroallergen encounter in naive mice and provide a priming source of IL-1 in adaptiveimmuneresponses.J.BiolRegul.Homeost.Agents., 28,91-103.
[30] Kim S, Prout M, et al.2010.Cutting edge basophils are transiently recruited into the draining lymph nodes
[31] Akash Verma, Marcel Wutrich, et al. Adaptive immunity to fungi cite the article as cold spring Harb Perspect. Med Doi.10.1101.esh Perspect. ao 19612.
[32] Michail S, Lionakis, li G, Netea and Steven M, Mendelian genetics of human susceptibility to fungal infection, cold spring Harbprospect.Med DOI 10.1101/csh Perspect.a019638Miha
[33] Ilse D. Jacobsen, Animal Models to Study Mucormycosis, Journal of Fungi,2019,5,27-MDPI
[34] Al-Awar A., Kupai K., Veszelka M., Szucs G., Attieh Z., Murlasits Z., Torok S., Posa A., Varga C. Experimental Diabetes Mellitus in Different Animal Models. J. Diabetes Res., (2016),9051426.
[35] Schwartze, V.U.; Jacobsen, I.D. Mucormycosis caused by the Lichtheimia species. Mycoses,57, (2014), 73–78 [CrossRef] [PubMed].
[36] Kamei, K. Animal models of zygomycosis—Absidia, Rhizopus, Rhizomucor, and Cunninghamella. Mycopathologia,152 (2001), 5–13.
[37] Lewis RE, KetoyiannisDP, Epidemiology, and treatment of mucormycosis external icon. Future Microbiol., 8(9)(2013), 1163-75.
[38] Kontoyiannis P, Lewis RE. How I treat mucormycosisexternal icon. Blood.,118(5), (2011),1216-1224.
[39] Pongas GN, Lewis RE, 2009. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? external icon ClinMicrobInfec., (2009),15 Suppl 5:93-7.
[40] John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosisexternal icon. Clin Microbiol Infect.,11(7) (2005), 515-7.
[41] Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, Chen J. Mucormycosis in renal transplant recipients: a review of 174 reported cases external icon. BMC Infect Dis., 17(1) (2017) ,283.
[42] Brad Spellberg, Thomas J. Walsh, Dimitrios P. Kontoyiannis,4 John Edwards, Jr.and Ashraf S. Ibrahim, Recent Advances in the Management of Mucormycosis:
[43] From Bench to Bedside, Clin Infect Dis.15; 48(12)(2009), 1743–1751.
[44] E.Jawetz, J.L.Malnick, E.A. Adelberg, A Lange Medical book Review of Medical Microbiology,17 th Edition
[45] Combination of debridement surgery and amphotericin B therapy was significantly better in the survival of the patients (P<0.005) than amphotericin B alone (79.6% vs. 51.7% survival). Thus, a rising trend of invasive zygomycosis was observed in patients with uncontrolled diabetes mellitus in India.
[46] Ajith Kumar AK, Rhino-orbital Cerebral Mucormycosis, start pearls article 64802,202
[47] Di Carlo P, Cabibi D, La Rocca AM, De Luca D, La Licata F, Sacco E. Post-bronchoscopy fatal endobronchial hemorrhage in a woman with bronchopulmonary mucormycosis: a case report. J Med Case Rep., (2010)4:398
[48] Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis; 41(1)(2005),60–66.
[49] Hamillos G, Samonis G, kontoyiannis DP. Pulmonary mucormycosis. SeminRespirCrit Care Med.,32(6), (2011),693–702.
[50] Spellberg B, Kontoyiannis DP, Fredericks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med,Mycol.,50(6)(2012),611–618.